Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Veterinary Active Pharmaceutical Ingredients Manufacturing Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The veterinary active pharmaceutical ingredients manufacturing market has experienced substantial growth in recent years. It is anticipated to expand from $8.03 billion in 2025 to $8.71 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.5%. The historical expansion of this market can be attributed to several factors including the increasing prevalence of animal diseases, the growing populations of livestock and companion animals, the expansion of the veterinary pharmaceutical industry, the development of conventional chemical-based APIs, and the rising demand for anti-infective and antiparasitic drugs.
The veterinary active pharmaceutical ingredients manufacturing market size is projected to experience substantial growth in the coming years, with an anticipated rise to $12.06 billion by 2030 at a compound annual growth rate (CAGR) of 8.5%. This expansion during the forecast period is driven by factors such as the adoption of biological and recombinant APIs, growth in contract manufacturing services, an increasing demand for highly potent APIs, supportive regulatory environments for veterinary pharmaceutical production, and a growing emphasis on vaccine API innovations. Major trends anticipated in this period include the expansion of contract manufacturing for veterinary APIs, the ongoing development of highly potent APIs, the enhancement of in-house API production capabilities, a heightened focus on anti-infective and antiparasitic APIs, and advancements in vaccine API formulations.
Get A Free Sample Report With In-Depth Market Insights:
Veterinary Active Pharmaceutical Ingredients Manufacturing Market Growth Drivers: What’s Behind The Acceleration?
The rising occurrence of zoonotic diseases is projected to drive the expansion of the veterinary active pharmaceutical ingredients manufacturing market in the future. Zoonotic diseases, also termed zoonoses, are infectious conditions naturally transmissible between animals and humans. Their increase stems from greater human-animal interaction, which facilitates pathogen transmission and new infections. Veterinary APIs are crucial for developing vaccines to prevent zoonotic disease transmission from animals to humans. Moreover, these APIs aid in combating antibiotic resistance, a significant challenge in managing zoonotic diseases. For example, data from February 2023, reported by the Council on Foreign Relations (CFR), indicated that up to 75% of new or emerging infectious diseases (EIDs) and 60% of known infectious diseases originate from zoonoses. Annually, zoonotic diseases are responsible for 2.7 million human fatalities and 2.5 billion instances of illness globally. Consequently, the growing frequency of zoonotic diseases is stimulating the expansion of the veterinary active pharmaceutical ingredients manufacturing market.
Veterinary Active Pharmaceutical Ingredients Manufacturing Market Breakdown By Product Type And Application
The veterinary active pharmaceutical ingredients manufacturing market covered in this report is segmented –
1) By Product: Antiparasitic, Anti-Infectives, Vaccines, NSAIDs
2) By Service Type: In House, Contract Outsourcing
3) By Synthesis Type: Chemical Based API, Biological API, Highly Potent API
Subsegments:
1) By Antiparasitic: Endectocides, Anthelmintics, Antiprotozoals
2) By Anti-Infectives: Antibiotics, Antifungals, Antivirals
3) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines
4) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Non-Selective NSAIDs, COX-2 Inhibitors
Veterinary Active Pharmaceutical Ingredients Manufacturing Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies in the veterinary active pharmaceutical ingredient manufacturing market are prioritizing the establishment of API production facilities to gain a competitive edge. These manufacturing plants for veterinary APIs are specialized facilities that produce the active pharmaceutical ingredients vital for formulating veterinary drugs. For example, in October 2023, Stallen South Asia Private Limited, an India-based animal health company, launched and commenced operations at a new veterinary API facility for Halquinol, which is a non-antibiotic growth promoter from the hydroxyquinoline group. This substance is a combination of 5-chloro-8-hydroxyquinoline, 5,7-dichloro-8-hydroxyquinoline, and 7-chloro-8-hydroxyquinoline. The facility produces products like Halquinol 98%, manufactured according to British Pharmacopeia 1980 (BP 80) guidelines. In addition to the more standard 60% and 12% forms, Stallen is capable of supplying 98% as a chemical API for veterinary formulations and feed additives. Stallen intends to decrease the animal health industry’s reliance on products imported from China by gradually introducing a broad spectrum of APIs from this plant.
Veterinary Active Pharmaceutical Ingredients Manufacturing Market Competitive Overview And Top Companies
Major companies operating in the veterinary active pharmaceutical ingredients manufacturing market are Alivira Animal Health Limited, Excel Industries Limited, Ofichem Group B.V., Jiangsu Lingyun Pharmaceutical Co. Ltd., SUANFARMA S.A., NGL Fine-Chem Limited, FIS – Fabbrica Italiana Sintetici S.p.A., Lupin Limited, Aurobindo Pharma Limited, Saneca Pharmaceuticals AS, Neuland Laboratories Limited, Divi’s Laboratories Limited, Zoetis Inc., Grupo Indukern S.L., Sequent Scientific Limited, Chempro Pharma Private Limited, AMGIS Lifescience Ltd., Huvepharma AD, Vetpharma Animal Health S.L., Qilu Pharma Spain S.A., INDUKERN Chemie AG, Chemopharma S.A., Norbrook Laboratories Limited, Ceva Santé Animale S.A., Vetoquinol S.A., Virbac S.A.
View The Full Veterinary Active Pharmaceutical Ingredients Manufacturing Market Report:
Veterinary Active Pharmaceutical Ingredients Manufacturing Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the veterinary active pharmaceutical ingredients manufacturing market in 2025. The regions covered in the veterinary active pharmaceutical ingredients manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
